FP

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers

News / By

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers TSY-110 is positioned to become the first biosimilar alternative to Roche’s Kadcyla® (ado-trastuzumab emtansine) in major regulated markets. TAIPEI, Taiwan — August 28, 2026 — Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the submission of a Clinical Trial Application …

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers Read More »

Formosa Pharmaceuticals Fulfills ESG Commitment with “Mind Mapping” Training and Eden Foundation Charity Donation

ESG / By

08/20/2026 Formosa Pharmaceuticals successfully hosted a comprehensive ESG event that integrated professional development with social charity. This initiative aimed to enhance our team’s workplace competitiveness while fulfilling our corporate social responsibility (CSR), demonstrating our unwavering commitment to employee growth and giving back to society. Investing in Employee Development and Efficient ThinkingThe day kicked off with …

Formosa Pharmaceuticals Fulfills ESG Commitment with “Mind Mapping” Training and Eden Foundation Charity Donation Read More »

Keeping Up with the Times! Formosa Pharmaceuticals Partners with Chingcheng Law Firm for Annual Employee Legal Training

ESG / By

05/08/2026 To continuously elevate our corporate governance standards and strengthen employees’ legal awareness, Formosa Pharmaceuticals successfully held its annual employee legal education and training session on May 8th. In an ever-changing business landscape, keeping up with the times is essential! We extend our deepest gratitude to Chingchen Law Firm for their continued support of our …

Keeping Up with the Times! Formosa Pharmaceuticals Partners with Chingcheng Law Firm for Annual Employee Legal Training Read More »

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

News / By

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery TAIPEI – June 11, 2026 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd …

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery Read More »

Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting

News / By

Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting TAIPEI, TAIWAN – May 22, 2026 – Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy of TSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinical Oncology (ASCO) …

Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting Read More »

Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases

News / By

Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases SINGAPORE / TAIPEI — April 30, 2026 – Formosa Pharmaceuticals, Inc. (“Formosa”, 6838.TW) and the Singapore Eye Research Institute (“SERI”) are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa’s …

Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases Read More »

Advancing Women’s Football Professionalization! Formosa Pharmaceuticals Supports Taipei Bravo’s Japan Exchange to Deepen International ESG Commitments

ESG / By

2026/4/20 To further its ESG sustainability initiatives and foster social prosperity, Formosa Pharmaceuticals supported the Taipei Bravo Women’s Football Team during their visit to sister club Viamaterras Miyazaki in Japan on April 18 and 19. The two-day international exchange included joint training sessions to refine technical skills and an invitation to attend a Viamaterras first-team …

Advancing Women’s Football Professionalization! Formosa Pharmaceuticals Supports Taipei Bravo’s Japan Exchange to Deepen International ESG Commitments Read More »

See the Power in the Small: Formosa Pharmaceuticals Supports Taipei Bravo Women’s Football in Spirited 2026 WBC Cheer Campaign, Fulfilling ESG Health Commitments

ESG / By

3/3/2025 As the 2026 World Baseball Classic (WBC) kicks off, a new wave of baseball fever is sweeping across Taiwan. Last night, the “Taipei Bravo Women’s Football Team,” sponsored by Formosa Pharmaceuticals (6838), joined several of the nation’s top athletic teams to offer their heartfelt support and blessings to Team Taiwan (Chinese Taipei) as they …

See the Power in the Small: Formosa Pharmaceuticals Supports Taipei Bravo Women’s Football in Spirited 2026 WBC Cheer Campaign, Fulfilling ESG Health Commitments Read More »

Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

News / By

Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery TAIPEI – February 23, 2026 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. (“Arrotex”), for exclusive …

Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery Read More »

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

News, Uncategorized / By

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery TAIPEI – January 12, 2026 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd …

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery Read More »

Scroll to Top